) -- Adam Feuerstein's take on the biotech week that was Oct. 18, 2010:

The weekly shocker: U.S. regulators reject

Amylin Pharmaceuticals'


diabetes drug Bydureon


Not everyone was surprised by the Bydureon decision.

Meet the short-seller who got Amylin right


Amylin's Really Bad Day:

Reader Mailbag


The week's best-performing stocks in the sector:










Aryx Therapeutics




(DDS) - Get Report


Alexza Pharmaceuticals



Valeant Pharmaceuticals


part ways over the delayed AZ-004.

Generex Biotechnology


exiled to the pink sheets.

Gilead Sciences

(GILD) - Get Report

earns 90 cents a share (adjusted) in the third quarter on total revenue of $1.94 billion, topping Street consensus.



forecasts 2011 earnings (adjusted) of $4.30-$4.60 a share, well above Street consensus of $3.85, and says


(SNY) - Get Report

is significantly undervaluing the company with its $69-a-share takeover offer. Based on the valuation multiple Sanofi is using today, Genzyme is worth $89 a share, Genzyme said.

Cell Therapeutics

(CTIC) - Get Report

issues press release about European regulatory sign-off on a plan to

study pixantrone in children

, then the company sells preferred shares convertible into 56.8 million common shares and warrants to raise $21 million.

This week's

Biotech Stock Mailbag


Titan Pharma

TheStreet Recommends



Mela Sciences



AVI Biopharma



Vanda Pharmaeuticals

(VNDA) - Get Report


Savient Pharmaceuticals



Transcept Pharmaceuticals


releases results from a highway driving study of its Intermezzo sleeping pill, plans to resubmit the drug to the FDA in the first quarter 2011.

The week's worst-performing stocks:

Amylin Pharmaceuticals




(ALKS) - Get Report


Molecular Insight Pharmaceuticals



Somaxon Pharmaceuticals



Senesco Technologies



Cubist Pharmaceuticals


sells $400 million in convertible debt.


paragraph IV generic challenge was filed against Silenor

, the sleeping pill recently launched by

Somaxon Pharmaceuticals



Alexion Pharmaceutials

(ALXN) - Get Report

announces positive, interim results from a pivotal study of Soliris in patients with atypical Hemolytic Uremic Syndrome. The company also reports third-quarter earnings of 50 cents a share on revenue of $141.6 million, topping Street consensus.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:


Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.